Image Place holder

Jose Sandoval Sus, MD

 
Specialty: Hematology/Oncology
Sub Specialty: Hematology, Medical Oncology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Overview

Cancer Focus: Hodgkin Lymphoma, Leukemia, MDS, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Dr. Jose Sandoval Sus is an assistant member of Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System in Pembroke Pines. He received his medical degree from Universidad Autonoma de Bucaramanga (UNAB). He worked as a hospitalist in the Hematology Oncology Department of a tertiary care hospital affiliated with UNAB (Clinica Carlos Ardila Lulle/FOSCAL). Following this, Dr. Sandoval Sus joined Moores Cancer Center at the University of California, San Diego as a postdoctoral research fellow in the research group of Dr. Thomas J. Kipps and Dr. Januario Castro, where he focused on phase I/II translational clinical trials in chronic lymphocytic leukemia (CLL). After working as a clinical instructor at UNAB in Colombia for six months, he completed an internal medicine internship and residency at the University of Miami/Jackson Memorial Medical Center. Dr. Sandoval Sus then was internal medicine chief resident at the Miami VA Healthcare System then completed a hematology and medical oncology fellowship at the University of South Florida/Moffitt Cancer Center in Tampa. During this time, Dr. Sandoval’s research focus was in prognostic and therapeutic aspects of lymphoid malignancies, with an emphasis in CLL and mantle cell lymphoma (MCL). His professional interests are in patient-focused care of all hematological malignancies, with a special emphasis in both indolent and aggressive lymphoid tumors.


Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of California, San Diego Moores Cancer Center - Clinical and Research Fellow
  • University of South Florida/Moffitt Cancer Center - Oncology / Hematology

Residency:

  • University of Miami - Jackson Memorial Hospital - Internal Medicine

Medical School:

  • Universidad Autonoma de Bucaramanga Medical School - MD
Participating Trials

CLINICAL TRIAL 90001
A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
Condition: Malignant Hematology
Intervention:
Open (affiliates only)

CLINICAL TRIAL 20814
Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group
Condition: Malignant Hematology
Intervention:
Open (affiliates only)

CLINICAL TRIAL 21056
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention:
Open (affiliates only)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 May.27(5):363-370. Pubmedid: 33965173.
  • Sandoval-Sus J, Chavez JC. The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Ther Adv Hematol. 2021 May.12. Pubmedid: 34104371. Pmcid: PMC8165824.
  • Chavez JC, Yassine F, Sandoval-Sus J, Kharfan-Dabaja MA. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. Int J Hematol Oncol. 2021 Jun.10(2):IJH33. Pubmedid: 34540198. Pmcid: PMC8445151.
  • Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
  • Sandoval-Sus JD, Brahim A, Khan A, Deutsch Y, Raphael B, Ansari-Lari A, Fernandez HF, Raez LE. Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. Clin Lymphoma Myeloma Leuk. 2020 Mar.20(3):e113-e117. Pubmedid: 32033930.
  • Rosas D, Yepes I, Tschanz J, Wariboko M, Sandoval-Sus JD. Epstein-Barr Virus: From Kissing Disease to Broken Heart. Cureus. 2020 Apr.12(4):e7704. Pubmedid: 32431983. Pmcid: PMC7233509.
  • Sandoval-Sus JD, Brahim A, Khan A, Raphael B, Ansari-Lari A, Ruiz M. Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. Int J Hematol. 2019 Jan.109(5):622-626. Pubmedid: 30671911.
  • Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019 Feb.60(2):309-316. Pubmedid: 29963932.
  • Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy for double-hit lymphoma. Drugs Context. 2019 Dec.8. Pubmedid: 31844420. Pmcid: PMC6905641.
  • Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA. Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. Blood Rev. 2018 Mar.32(2):159-166. Pubmedid: 29122300.
  • Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jan.59(1):59-68. Pubmedid: 28641468. Pmcid: PMC7771359.
  • Sandoval-Sus J, Sotomayor EM, Shah BD. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematol Oncol Stem Cell Ther. 2017 Sep.10(3):99-115. Pubmedid: 28404221.
  • Juárez-Salcedo LM, Sandoval-Sus J, Sokol L, Chavez JC, Dalia S. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. Crit Rev Oncol Hematol. 2017 May.113:52-62. Pubmedid: 28427522.
  • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jaglal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun.5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
  • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S170-S174. Pubmedid: 27521314.
  • Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol. 2015 Jun.90(6):E111-E116. Pubmedid: 25737247. Pmcid: PMC4439262.

Patient Comments
Overall Satisfaction

patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments